EUCTR2020-001648-24-PT进行中（未招募）1 期
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria. (ABIGAIL) - Abemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL: ABIGAI
Medica Scientia Innovation Research (MEDSIR)0 个研究点目标入组 160 人开始时间: 2021年6月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed ICF prior to participation in any study-related activities
- •2.Male/female patients =18 years at the time of signing the ICF
- •3.ECOG performance status of 0 or 1
- •4.Life expectancy of at least 24 weeks
- •5.Pre-menopausal,peri-menopausal and post-menopausal women as defined by any of the following criteria:
- •a.Documented bilateral oophorectomy
- •b.Age =60 years
- •c.Age <60 years and cessation of regular menses for =12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory’s reference range for post-menopausal females
- •6.Unresectable locally advanced or metastatic breast cancer (MBC) that is not amenable to
- •resection with curative intent
- •7.At least one of the following aggressive disease criteria:
- •a.Presence of visceral disease
- •b.Either radiological as per RECIST v1.1 or Clinical evidence of progressive disease (PD) on or within 36 months of completing adjuvant endocrine therapy (ET)
- •c. High histological grade and/or PgR-negative status on primary tumor
- •d. LDH >1.5 × the upper limit of normal (ULN)
- •8. Histologically confirmed estrogen receptor-positive and/or progesterone
- •receptor (PgR)-positive and HER2-negative breast cancer based on local testing on the most recent analyzed biopsy.
- •9. Measurable disease as per RECIST v 1.1 with at least one site of disease amenable to biopsy. Patients with bone lesions as the only sites of metastatic disease are not eligible, except for patients with identifiable soft tissue components, evaluable by cross sectional imaging techniques such as CT or magnetic resonance imaging (MRI), and that meet the definition of measurability according to RECIST v1.1.
- •10.Willingness and ability to provide a tumor biopsy from a metastatic site or the primary breast tumor at the time of the inclusion and at the time of treatment progression (if feasible) and at the time of treatment progression (if feasible) to perform exploratory studies. If not feasible, patient eligibility should be evaluated by Sponsor’s qualified designee.
- •11. Willingness to provide blood samples for exploratory studies at baseline, after 2 weeks (Cycle [C]1, day [D]15) of study treatment, 4 weeks (C2D1), 12 weeks (at the primary efficacy endpoint, corresponding to C4D1), 4 weeks from the initiation of abemaciclib-containing treatment, and at progression (or
- •study treatment termination prior to starting second-line
- •treatment).
- •12. Willingness to provide stool samples plus Patient-Reported Food Frequency Questionnaires for exploratory studies at study entry (baseline), 4 weeks after the start of treatment (C2D1), and at time of disease progression. Patients on Arm B will also have a stool sample collected 4 weeks from the initiation of
- •abemaciclib-containing treatment.
- •13. Patients relapsing on a cyclin-dependent kinase (CDK)4/6 inhibitor-based regimen in the neoadjuvant or adjuvant setting will be suitable for the study if disease progression is confirmed after at least 12 months following CDK 4/6 treatment completion.
- •14.No prior systemic therapy for unresectable locally advanced or
- •metastatic disease
- •15.Radiation therapy for metastatic disease is permitted but the patient must have fully recovered from the acute effects and at least 14 days must have elapsed between the last dose and randomization.
- •16.Resolution of all acute toxic effects of prior anti-cancer therapy
- •to Grade =1 as determined by the NCI-CTCAE v 5.0 (except for
- •Grade =2 neuropathy, alopecia, or other toxi
排除标准
- •1.Known hypersensitivity to abemaciclib, letrozole, fulvestrant, paclitaxel, and/or any of their excipients
- •2.Are currently receiving an investigational drug in a clinical study or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
- •3.Formal contraindication to ET defined as visceral crisis and rapidly or symptomatic progressive visceral disease
- •4.Known concurrent malignancy or malignancy within 5 years of study enrollment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk of recurrence, discussion with the medical monitor is required
- •5.Known active brain metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for =4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for =14 days prior to first dose of study treatment
- •6.Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
- •7.Major surgical procedure within 14 days prior to treatment initiation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis
- •8. Active bleeding diathesis, venous thrombo-embolism, previous history of bleeding diathesis, or chronic anti-coagulation treatment, or any indications or history of Disseminated Intravascular Coagulation (DIC) or Deep vein thrombosis (DVT)
- •9.Serious and/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g., estimated creatinine clearance <30 ml/min], history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn’s disease or ulcerative colitis or a pre-existing chronic condition resulting in baseline Grade 2 or higher diarrhea)
- •10.Current known infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
- •11.Active bacterial or fungal infection at the time of enrolment (requiring antibiotics or antifungal agents at time of initiating study treatment)
- •12.History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- •13.Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 3 weeks after the last dose of study treatment
研究者
相似试验
进行中（未招募）
1 期
A study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant)with or without a short course of chemotherapy with paclitaxel in patients withunresectable locally advanced or metastatic breast cancer with aggressive disease criteria.Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease criteria.MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2020-001648-24-ITMEDICA SCIENTIA INNOVATION RESEARCH S.L.160
招募中
1 期
A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864CTIS2024-512821-10-00Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group90
进行中（未招募）
1 期
A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/ taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004384-39-ATAustrian Breast & Colorectal Cancer Study Group (ABCSG)90
进行中（未招募）
1 期
An open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancerprimary breast cancerEUCTR2011-004822-85-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)
进行中（未招募）
1 期
Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARPeoadjuvant TNBCMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2010-018960-17-DEsanofi-aventis recherche & développement